Andrey V Grechko

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8769355/andrey-v-grechko-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65	1,504	21	37
papers	citations	h-index	g-index
74	2,218 ext. citations	3.3	5.33
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
65	Microbiota dysfunction in patients with brain damage in chronic critical condition. <i>Russian Neurological Journal</i> , 2022 , 27, 94-104	0.2	
64	The spectrum of vital activity restrictions in disabled people due to thyroid cancer. <i>Medical and Social Expert Evaluation and Rehabilitation</i> , 2021 , 24, 33-40	0.3	
63	Prospects of using adaptive phage therapy in the rehabilitation of post-COVID-19 patients. <i>Physical and Rehabilitation Medicine Medical Rehabilitation</i> , 2021 , 3, 254-259	0.4	O
62	The Role of Mitochondrial Dysfunction in Vascular Disease, Tumorigenesis, and Diabetes. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 671908	5.6	9
61	Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	10
60	Mitochondrial Dysfunction in Vascular Wall Cells and Its Role in Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
59	Cellular Mechanisms of Human Atherogenesis: Focus on Chronification of Inflammation and Mitochondrial Mutations. <i>Frontiers in Pharmacology</i> , 2020 , 11, 642	5.6	13
58	Mitochondrial Dysfunction and DNA Damage in the Context of Pathogenesis of Atherosclerosis. <i>Biomedicines</i> , 2020 , 8,	4.8	15
57	The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	125
56	In Search for Genes Related to Atherosclerosis and Dyslipidemia Using Animal Models. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
55	Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	15
54	Lipid-based gene delivery to macrophage mitochondria for atherosclerosis therapy. <i>Pharmacology Research and Perspectives</i> , 2020 , 8, e00584	3.1	9
53	Nosocomial Pneumonia: An Update on Early Diagnosis and Prevention. <i>Current Respiratory Medicine Reviews</i> , 2020 , 15, 251-259	0.3	1
52	Novel Approaches to Anti-atherosclerotic Therapy: Cell-based Models and Herbal Preparations (Review of Our Own Data). <i>Current Drug Discovery Technologies</i> , 2020 , 17, 278-285	1.5	
51	The role of sialic acids in the initiation of atherosclerosis. <i>Minerva Cardioangiologica</i> , 2020 , 68, 359-364	1.1	2
50	A brief overview of currently used atherosclerosis treatment approaches targeting lipid metabolism alterations. <i>American Journal of Cardiovascular Disease</i> , 2020 , 10, 62-71	0.9	2
49	Neurodegenerative Diseases Associated with Mitochondrial DNA Mutations. <i>Current Pharmaceutical Design</i> , 2020 , 26, 103-109	3.3	3

(2019-2020)

48	The role of mitochondria in cardiovascular diseases related to atherosclerosis. <i>Frontiers in Bioscience - Elite</i> , 2020 , 12, 102-112	1.6	5
47	Medical rehabilitation at a new coronavirus infection (COVID-19). <i>Physical and Rehabilitation Medicine Medical Rehabilitation</i> , 2020 , 2, 140-189	0.4	11
46	NADPH Oxidases and Their Role in Atherosclerosis. <i>Biomedicines</i> , 2020 , 8,	4.8	22
45	Sialidase Activity in Human Blood Serum Has a Distinct Seasonal Pattern: A Pilot Study. <i>Biology</i> , 2020 , 9,	4.9	1
44	Oxidative Stress and Antioxidants in Atherosclerosis Development and Treatment. <i>Biology</i> , 2020 , 9,	4.9	30
43	Contribution of Neurotrophins to the Immune System Regulation and Possible Connection to Alcohol Addiction. <i>Biology</i> , 2020 , 9,	4.9	4
42	Heteroplasmic Variants of Mitochondrial DNA in Atherosclerotic Lesions of Human Aortic Intima. <i>Biomolecules</i> , 2019 , 9,	5.9	7
41	Nosocomial Tracheobronchitis and Pneumonia Continuum - Target for Inhaled Antibiotics?. <i>Current Respiratory Medicine Reviews</i> , 2019 , 14, 135-141	0.3	
40	Foam cell formation and cholesterol trafficking and metabolism disturbances in atherosclerosis. <i>Cor Et Vasa</i> , 2019 , 61, 48-55	0.3	6
39	Protection of the Rights of Disabled People to Access Medicines. <i>Advances in Gerontology</i> , 2019 , 9, 56-6	510.4	О
38	Changes in Mitochondrial Genome Associated with Predisposition to Atherosclerosis and Related Disease. <i>Biomolecules</i> , 2019 , 9,	5.9	17
37	The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	50
36	MicroRNAs as Potential Biomarkers in Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	42
35	Immune-Inflammatory Responses in Atherosclerosis: The Role of Myeloid Cells. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	26
34	Molecular Markers of Ischemic Stroke. <i>Obshchaya Reanimatologiya</i> , 2019 , 15, 11-22	0.8	4
33	Transcriptional Characteristics of Activated Macrophages. Current Pharmaceutical Design, 2019 , 25, 213	- <u>3</u> .137	4
32	Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy. <i>Current Pharmaceutical Design</i> , 2019 , 25, 635-641	3.3	7
31	Trans-sialidase Associated with Atherosclerosis: Defining the Identity of a Key Enzyme Involved in the Pathology. <i>Current Drug Targets</i> , 2019 , 20, 938-941	3	3

30	Defects of Red Blood Cell Membranes in Patients with Brain Dysfunction (Pilot Study). <i>Obshchaya Reanimatologiya</i> , 2019 , 15, 11-20	0.8	1
29	Sialidase activity in human pathologies. European Journal of Pharmacology, 2019 , 842, 345-350	5.3	30
28	Potential of anti-inflammatory agents for treatment of atherosclerosis. <i>Experimental and Molecular Pathology</i> , 2018 , 104, 114-124	4.4	61
27	New biomarkers for diagnosis and prognosis of localized prostate cancer. <i>Seminars in Cancer Biology</i> , 2018 , 52, 9-16	12.7	37
26	The role of monocytosis and neutrophilia in atherosclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2018 , 22, 1366-1382	5.6	37
25	Data on association of mitochondrial heteroplasmy and cardiovascular risk factors: Comparison of samples from Russian and Mexican populations. <i>Data in Brief</i> , 2018 , 18, 16-21	1.2	6
24	Mitochondrial genome variability: the effect on cellular functional activity. <i>Therapeutics and Clinical Risk Management</i> , 2018 , 14, 237-245	2.9	4
23	Monitoring of the Effectiveness of Intensive Care and Rehabilitation by Evaluating the Functional Activity of the Autonomic Nervous System in Patients with Brain Damage. <i>Obshchaya Reanimatologiya</i> , 2018 , 14, 21-34	0.8	2
22	Diagnostics and Therapy of Human Diseases - Focus on Sialidases. <i>Current Pharmaceutical Design</i> , 2018 , 24, 2870-2875	3.3	3
21	MODERN ASPECTS OF THE RELATIONSHIP BETWEEN THE FUNCTIONAL STATE OF THE AUTONOMIC NERVOUS SYSTEM AND CLINICAL AND LABORATORY INDICES OF THE BODYIS HOMEOSTASIS IN BRAIN INJURIES. <i>Alexander Saltanov Intensive Care Herald</i> , 2018 , 79-86	0.8	4
20	Infusion Effect on Postoperative Intestinal Failure. Obshchaya Reanimatologiya, 2018, 14, 50-57	0.8	3
19	The role of mitochondrial dysfunction in cardiovascular disease: a brief review. <i>Annals of Medicine</i> , 2018 , 50, 121-127	1.5	165
18	Role of androgens in cardiovascular pathology. Vascular Health and Risk Management, 2018, 14, 283-29	04.4	26
17	Vasculoprotective Role of Olive Oil Compounds via Modulation of Oxidative Stress in Atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2018 , 5, 188	5.4	25
16	Inhibition of sialidase activity as a therapeutic approach. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 3431-3437	4.4	22
15	Mitochondrial diseases caused by mtDNA mutations: a mini-review. <i>Therapeutics and Clinical Risk Management</i> , 2018 , 14, 1933-1942	2.9	29
14	Matrix metalloproteinases in pro-atherosclerotic arterial remodeling. <i>Journal of Molecular and Cellular Cardiology</i> , 2018 , 123, 159-167	5.8	37
13	Impact of the cardiovascular system-associated adipose tissue on atherosclerotic pathology. Atherosclerosis, 2017, 263, 361-368	3.1	32

LIST OF PUBLICATIONS

12	Phytoestrogen-Rich Natural Preparation for Treatment of Climacteric Syndrome and Atherosclerosis Prevention in Perimenopausal Women. <i>Phytotherapy Research</i> , 2017 , 31, 1209-1214	6.7	12
11	Sialidases: Therapeutic and Antiatherogenic Potential. Current Pharmaceutical Design, 2017, 23, 4696-4	179.13	6
10	Mechanisms of foam cell formation in atherosclerosis. <i>Journal of Molecular Medicine</i> , 2017 , 95, 1153-11	1 65 .5	250
9	Role of lipids and intraplaque hypoxia in the formation of neovascularization in atherosclerosis. <i>Annals of Medicine</i> , 2017 , 49, 661-677	1.5	12
8	Thrombospondins: A Role in Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	29
7	Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2017 , 2017, 1273042	6.7	133
6	Calcifying Matrix Vesicles and Atherosclerosis. <i>BioMed Research International</i> , 2017 , 2017, 7463590	3	31
5	Small dense and desialylated low density lipoprotein in diabetic patients. Vessel Plus, 2017, 1,	2.3	6
4	Gender Peculiarities of Postresuscitation in the Expression of Brain-Derived Neurotrophic Factor (BDNF). <i>Obshchaya Reanimatologiya</i> , 2017 , 13, 44-57	0.8	2
3	Relationship between Morphofunctional Changes in Open Traumatic Brain Injury and the Severity of Brain Damage in Rats. <i>Bulletin of Experimental Biology and Medicine</i> , 2016 , 161, 419-24	0.8	1
2	Potential use of buccal epithelium for genetic diagnosis of atherosclerosis using mtDNA mutations. Vessel Plus,	2.3	13
1	Chemical composition of circulating native and desialylated low density lipoprotein: what is the difference?. <i>Vessel Plus</i> ,	2.3	19